Evaxion biotech announces pricing of $24.0 million follow-on public offering

Copenhagen, denmark, nov. 05, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the pricing of its follow-on public offering of 3,428,571 american depositary shares ("adss"), at a public offering price of $7.00 per ads, with each such ads representing one ordinary share, dkk 1 nominal value per share, of evaxion (the "ordinary shares"). the gross proceeds from the offering are expected to be approximately $24.0 million before deducting underwriting fees, commissions and other offering expenses. evaxion has granted the underwriters an option for a period of 30 days from the date of the final prospectus to purchase an additional 514,285 adss at the follow-on public offering price.
EVAX Ratings Summary
EVAX Quant Ranking